First Capital Advisors Group’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

First Capital Advisors Group’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$213K	Hold	3,476	–	–	0.11%	132
2023 Q1	$218K	Hold	3,476	–	–	0.14%	127
2022 Q4	$221K	Hold	3,476	–	–	0.15%	134
2022 Q3	$205K	Hold	3,476	–	–	0.17%	134
2022 Q2	$201K	Buy	+3,476	New	+$200K	0.14%	159
2018 Q4	–	Sell	-3,476	Closed	-$207K	–	172
2018 Q3	$207K	Buy	+3,476	New	+$203K	0.13%	161
2018 Q2	–	Sell	-3,476	Closed	-$171K	–	588
2018 Q1	$171K	Buy	+3,476	New	+$177K	0.1%	182

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CreativeOne Wealth Overland Park, Kansas $4.31B AUM 19.42% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

IFWM

Institute for Wealth Management Denver, Colorado $938M AUM 29.36% 1-Year Est. Return

First Capital Advisors Group's PBE Position: Q2 2023 in Review

First Capital Advisors Group held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q2 2023 at 3,476 shares worth $213K. The position accounts for 0.11% of the portfolio, ranked #132.

First Capital Advisors Group first reported a position in PBE in Q1 2018 and has held it in 7 quarters since. The position peaked at $221K in Q4 2022. 96 funds tracked by Wall St. Rank hold PBE as of Q2 2023.

First Capital Advisors Group held 3,476 shares of Invesco Biotechnology & Genome ETF worth $213K as of Q2 2023.
First Capital Advisors Group left its Invesco Biotechnology & Genome ETF share count unchanged in Q2 2023.
Invesco Biotechnology & Genome ETF made up 0.11% of First Capital Advisors Group's portfolio in Q2 2023, its #132 holding.
First Capital Advisors Group first reported a position in Invesco Biotechnology & Genome ETF in Q1 2018 and has held it in 7 quarters since.
First Capital Advisors Group's Invesco Biotechnology & Genome ETF position peaked at $221K in Q4 2022.
96 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2023.

Based on First Capital Advisors Group's 13F filing for Q2 2023, filed 15 Aug 2023.